AMN is characterized by dark reddish macular lesions and retinal ischemia, with bilateral ocular changes noted in most patients. Retinal perfusion deficits and inner retinal changes were identified, ...

Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision loss in "wet" age-related macular degeneration and diabetic eye disease.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. After injury, severed axons separated from ...

Age-related macular degeneration (AMD) causes your central vision to get worse as you get older. An estimated 19.6 million people over 40 live with AMD, and nearly 1.5 million of them have their ...

The U.S. Department of Defense awarded just under $514,000 to an interdisciplinary team of researchers at the U of A to study the efficacy of “self-delivering” gene editors in the treatment of ...

But EyePoint appears to have reversed its fortunes thanks to positive new interim data on its lead asset in diabetic macular edema (DME). In the midstage VERONA trial, Duravyu delivered “early ...

Sadyr Japarov, president of the Kyrgyz Republic, addresses the general debate of the General Assembly’s 79th session. In light of these events, the speeches delivered by the five Central Asian ...

This therapy delivers the proprietary tyrosine kinase inhibitor vorolanib through the bioerodible Durasert E platform, designed for patients with diabetic macular edema (DME). According to the company ...

The study was published Thursday in JAMA Ophthalmology. Advertisement Macular degeneration is the most frequent cause of irreversible vision loss in the developed world. It affects the macula ...

Returning from the 2024 American Academy of Ophthalmology Annual Meeting in Chicago, Dr Garg highlights several important studies on diabetic macular edema (DME). One key study focused on the ...